PhoreMost Ltd.

https://www.phoremost.com

Twitter: @PhoreMostLtd

PhoreMost has developed a next-generation phenotypic drug discovery technology called SITESEEKER®, which uses the power of live-cells to discern the best new targets for future therapy and crucially, how to drug them. Based on ‘Protein Interference’ (PROTEINi®); a new genome-wide target identification & validation platform created by PhoreMost, SITESEEKER® can now systematically reveal critical druggable target-sites in any particular disease setting and then convert this information rapidly into novel small-molecule therapeutics. Using SITESEEKER®, PhoreMost is exclusively developing first-in-class targets for a range of unmet diseases and will collaborate with other pharmaceutical companies also wishing to engage in ‘Drugging the Undruggable®’. www.phoremost.com *

	Start	2015-04-07 established
	Industry	drug discovery
	Industry 2	Siteseeker® drug target discovery technology
	Person	Torrance, Chris (PhoreMost 201504– CEO + Co-founder before Horizon Discovery Co-founder + Vernalis)
	Person 2	Milner, Jonathan (Abcam 201409 Deputy Chairman + largest shareholder before CEO + Co-founder)

	Region	Babraham, Cambridgeshire
	Country	United Kingdom (GB)
	Street	Building B580, Room 2011 Babraham Research Campus
	City	CB22 3AT Babraham, Cambridgeshire
	Tel	+44-1223-804163
		Address record changed: 2021-04-27

Basic data	Employees	n. a.

		* Document for ï¿½About Sectionï¿½:

		Record changed: 2021-03-27